348 results on '"Bergmann, Martin W."'
Search Results
2. The ALSTER-FLX Registry: 3-Month outcomes after left atrial appendage occlusion using a next-generation device, a matched-pair analysis to EWOLUTION
3. Incidence and predictors of 2-year mortality following percutaneous left atrial appendage occlusion in the EWOLUTION trial.
4. Positionspapier „Schlafmedizin in der Kardiologie“, Update 2021
5. Treatment With an Interatrial Shunt in Heart Failure
6. Heart failure with preserved ejection fraction in patients with moderate/severe aortic stenosis: what harms our patients most?
7. Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion
8. Persistent and Recurrent Device-Related Thrombus After Left Atrial Appendage Closure
9. Limitations in Contemporary Pharmacological Stroke Prevention Therapies in Atrial Fibrillation: A Descriptive Literature Review
10. Higher in-hospital mortality in SARS-CoV-2 omicron variant infection compared to influenza infection—Insights from the CORONA Germany study
11. Improving Left Atrial Appendage Closure
12. Prevention and Management of Complications
13. Access to the Left Atrium
14. Practical Watchman Implantation
15. Combined Procedures
16. Background: Stroke Prevention in Patients with Atrial Fibrillation
17. Practical Watchman Implantation: Case Examples
18. Safety and Efficacy of LAA Closure
19. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN
20. Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction
21. Medikamentöse Kontrolle kardiovaskulärer Risikofaktoren bei HIV-Patienten unter ART Therapie
22. LAA occluder device for stroke prevention: Data on WATCHMAN and other LAA occluders
23. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure
24. Orale Antikoagulation und Plättchenhemmung nach Vorhofohrverschluss
25. Left atrial appendage closure in end‐stage renal disease and hemodialysis: Data from a German multicenter registry
26. Atrial Giant Cell Myocarditis as a Cause of Heart Failure
27. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage
28. Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock: Matched-Pair IABP-SHOCK II Trial 30-Day Mortality Analysis
29. Sex‐related differences in outcome after left atrial appendage occlusion: Insights from Europe and the EWOLUTION registry.
30. Clinical Cases in LAA Occlusion
31. Effect of allogeneic adipose tissue‐derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial.
32. Intramyocardial injections of erythropoietin-analogue C.E.R.A. in ischemic cardiomyopathy: the ALSTER C.E.R.A. trial
33. No Evidence of “Obesity Paradox” After Treatment With Drug-Eluting Stents in a Routine Clinical Practice: Results From the Prospective Multicenter German DES.DE (German Drug-Eluting Stent) Registry
34. Heart failure with preserved ejection fraction in patients with moderate/severe aortic stenosis: what harms our patients most?
35. β-Catenin Downregulation Attenuates Ischemic Cardiac Remodeling through Enhanced Resident Precursor Cell Differentiation
36. Prognostic Impact of Acute Cardiovascular Events in COVID-19 Hospitalized Patients—Results from the CORONA Germany Study
37. B-PO01-078 REAL-WORLD CLINICAL OUTCOMES WITH A NEXT-GENERATION LEFT ATRIAL APPENDAGE CLOSURE DEVICE: FIRST REPORT FROM THE FLXIBILITY POST-APPROVAL STUDY
38. Delivery of a bioresorbable vascular scaffold to complex lesions
39. Cardiac tamponade due to coronary perforation during percutaneous interventions successfully treated with microspheres
40. Genetic Background Defines the Regulation of Postnatal Cardiac Growth by 17β-Estradiol Through a β-Catenin Mechanism
41. True Efficacy of LAA Closure: Patient Outcomes on Long-term Single-Antiplatelet or No Therapy: Insights From the EWOLUTION Registry.
42. [beta]-Catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation
43. Krueppel-like factor 15 regulates Wnt/β-catenin transcription and controls cardiac progenitor cell fate in the postnatal heart
44. A pilot study of chronic, low-dose epoetin-β following percutaneous coronary intervention suggests safety, feasibility, and efficacy in patients with symptomatic ischaemic heart failure
45. Evaluation of Myocardial Gene Expression Profiling for Superior Diagnosis of Idiopathic Giant-Cell Myocarditis and Clinical Feasibility in a Large Cohort of Patients with Acute Cardiac Decompensation
46. The atrial flow regulator: current overview on technique and first experience
47. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: Design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial
48. MEF2 transcriptional activity maintains mitochondrial adaptation in cardiac pressure overload
49. NF-κB activation is required for adaptive cardiac hypertrophy
50. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.